Forget comparisons to Disc and other similar companies, a...

Forget comparisons to Disc and other similar companies, a company (GYG) that sells crappy tacos and has zero growth runway left is worth over $3 billion, whilst the cash printing Clinuvel with a monopoly position and an absolutely enormous growth runway ahead of it is valued at only $750 million (deduct $200m cash to get a more accurate valuation). Yet another stock showing just how undervalued Clinuvel is. A 25x earnings multiple is what you might expect for a steadily growing but slow growth and largely mature company, so in the case of CUV, in addition to being a low valuation for a growing pharma company with a monopoly position, it gives a value of zero to the pipeline assets which have the potential to make the existing EPP revenue and earnings appear akin to a spec of sand within a large beach (the large beach being the potential market size for Clinuvel's products if they can execute). True some of these assets are a ways away from generating cash flows, but the Vitiligo opportunity is certainly quite close now (P3 trial well underway), and so to is the enormous cosmetic opportunity. Even for those assets further away from becoming cash flow generative, a valuation of zero is still completely inappropriate. Peter Lynch would see this as an asset play, an opportunity to pay absolutely nothing for the "hidden assets" of a company (a freebie).